A Phase 1 Study of a Prostate-Specific Membrane Antigen Targeting-Tubulysin Conjugate EC1169 in Patients with Recurrent Metastatic Castration-Resistant Prostate Cancer (mCRPC)
-
- STATUS
- Not Recruiting
Summary
The purpose of this study is to determine the safety of EC1169 and the best dose to use in humans in future studies. This study will also determine how EC1169 is distributed, broken down, passed and absorbed through your body and how quickly it is eliminated (leaves the body).
Description
The purpose of this study is to determine the safety of EC1169 and the best dose to use in humans in future studies. This study will also determine how EC1169 is distributed, broken down, passed and absorbed through the body and how quickly it is eliminated.
Details
| Condition | prostate cancer |
|---|---|
| Age | 18years - 100years |
| Clinical Study Identifier | TX7716 |
| Last Modified on | 19 February 2024 |
Similar trials to consider
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteerStudy Definition
WikipediaAdd a private note
- Select a piece of text.
- Add notes visible only to you.
- Send it to people through a passcode protected link.